GlassScriptPhysician profile
Anthony W Clay
NPI 1649202573
$36,570.40
in general payments reported to CMS, 2019-2025
26 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,376 · 2020: $8,903 · 2021: $12K · 2022: $7,851 · 2023: $3,944 · 2024: $2,161 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,122 · Food and Beverage: $1,229 · Travel and Lodging: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,122.00 |
| Food and Beverage | $1,229.47 |
| Travel and Lodging | $933.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $25,934.35 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $6,802.58 | 2019-2023 | |
| Janssen Research & Development, LLC | $1,223.22 | 2023 | |
| Pfizer INC. | $796.18 | 2019-2025 | |
| Akcea Therapeutics, INC. | $287.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $267.50 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $257.88 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $245.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $193.75 | 2022-2023 | Verquvo |
| Amarin Pharma, INC. | $149.80 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $78.80 | 2024 | Xarelto |
| Esperion Therapeutics, INC. | $69.94 | 2020-2021 | |
| Lundbeck LLC | $40.86 | 2019 | |
| Alnylam Pharmaceuticals INC. | $30.68 | 2019 | |
| Amgen INC. | $28.01 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $24.24 | 2019 | |
| Daiichi Sankyo INC. | $22.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.62 | 2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $19.11 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $18.23 | 2019 | |
| Boston Scientific Corporation | $17.60 | 2019 | |
| Gilead Sciences, INC. | $14.87 | 2019 | |
| Siemens Medical Solutions USA, INC. | $13.53 | 2025 | Syngo.Via, Syngo Dynamics |
| Kowa Pharmaceuticals America, INC. | $12.91 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Clay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.